Opal (Cullinan Oncology)

Opal (Cullinan Oncology): sourced facts only. name: "In a competition ELISA assay, Opal effectively blocked wt PD1 from binding to PDL1 and PDL2." [DOI:10.1158/1538-7445.am2022-2076]; target: "In a competition ELISA assay, Opal effectively blocked wt PD1 from binding to PDL1 and PDL2." [DOI:10.1158/1538-7445.am2022-2076]; target: "In a competition ELISA assay, Opal effectively blocked wt PD1 from binding to PDL1 and PDL2." [DOI:10.1158/1538-7445.am2022-2076]; developer: "1Cullinan Oncology, Inc., Cambridge, MA." [DOI:10.1158/1538-7445.am2022-2076]; modality: "Opal is a conditional 4-1BB agonistic fusion protein comprising trimerized 4-1BB ligand and a high affinity variant of the extracellular domain of PD-1" [DOI:10.1158/1538-7445.am2022-2076]; stage: "When tumor-bearing mice were treated IP with Opal at 1 mg/kg, 7/10 mice exhibited durable cures without significant body weight loss." [DOI:10.1158/1538-7445.am2022-2076]